DK1001792T3 - Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser - Google Patents

Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser

Info

Publication number
DK1001792T3
DK1001792T3 DK98937862T DK98937862T DK1001792T3 DK 1001792 T3 DK1001792 T3 DK 1001792T3 DK 98937862 T DK98937862 T DK 98937862T DK 98937862 T DK98937862 T DK 98937862T DK 1001792 T3 DK1001792 T3 DK 1001792T3
Authority
DK
Denmark
Prior art keywords
physiologically acceptable
complexes
salts
vanadium compounds
acceptable vanadium
Prior art date
Application number
DK98937862T
Other languages
Danish (da)
English (en)
Inventor
Conradus Ghosal Gho
Original Assignee
Gho St Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gho St Holding Bv filed Critical Gho St Holding Bv
Application granted granted Critical
Publication of DK1001792T3 publication Critical patent/DK1001792T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98937862T 1997-07-29 1998-07-29 Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser DK1001792T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1006681A NL1006681C2 (nl) 1997-07-29 1997-07-29 Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
PCT/NL1998/000431 WO1999006056A1 (fr) 1997-07-29 1998-07-29 Utilisation de composes, de sels et de complexes de vanadium acceptables sur le plan physiologique

Publications (1)

Publication Number Publication Date
DK1001792T3 true DK1001792T3 (da) 2004-01-19

Family

ID=19765422

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98937862T DK1001792T3 (da) 1997-07-29 1998-07-29 Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser

Country Status (22)

Country Link
US (2) US6579540B1 (fr)
EP (1) EP1001792B1 (fr)
JP (1) JP2001511454A (fr)
CN (1) CN1104244C (fr)
AT (1) ATE253373T1 (fr)
AU (1) AU738701B2 (fr)
BR (1) BR9811298A (fr)
CA (1) CA2298645C (fr)
CZ (1) CZ299716B6 (fr)
DE (1) DE69819514T2 (fr)
DK (1) DK1001792T3 (fr)
EA (1) EA002574B1 (fr)
ES (1) ES2207851T3 (fr)
ID (1) ID24870A (fr)
IL (2) IL134259A0 (fr)
NL (1) NL1006681C2 (fr)
NO (1) NO20000446L (fr)
NZ (1) NZ502613A (fr)
PL (1) PL338415A1 (fr)
PT (1) PT1001792E (fr)
TR (1) TR200000349T2 (fr)
WO (1) WO1999006056A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
US8192994B2 (en) * 1998-02-10 2012-06-05 Angros Lee H Method of applying a biological specimen to an analytic plate
WO2001045716A1 (fr) * 1999-12-20 2001-06-28 Gho'st Holding B.V. Composition pharmaceutique comprenant un compose, un sel ou un complexe de vanadium, acceptable au plan physiologique, et un inhibiteur d'echange na?+/h+¿
WO2003041703A2 (fr) * 2001-11-16 2003-05-22 Gho Holding B.V. Methode de traitement des brulures
AR065121A1 (es) 2007-01-31 2009-05-20 Basf Plant Science Gmbh Plantas con rasgos aumentados relacionados con el rendimiento y/o resistencia incrementada al estres abiotico y un metodo para desarrollar las mismas
EP2069509B1 (fr) 2007-05-03 2013-09-18 BASF Plant Science GmbH Plantes possédant des traits de rendement amélioré et procédé de fabrication
DE112008001879T5 (de) 2007-07-20 2010-07-29 Basf Plant Science Gmbh Pflanzen mit verbesserten Ertragsmerkmalen und Verfahren zu irer Herstellung
AR067748A1 (es) 2007-07-31 2009-10-21 Basf Plant Science Gmbh Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas
WO2009056566A2 (fr) 2007-10-29 2009-05-07 Basf Plant Science Gmbh Plantes dotées de traits de rendement améliorés et procédé de fabrication
WO2009135810A1 (fr) 2008-05-05 2009-11-12 Basf Plant Science Gmbh Plantes présentant des traits relatifs au rendement améliorés et leur procédé de fabrication
US20100078320A1 (en) * 2008-09-26 2010-04-01 Applied Materials, Inc. Microwave plasma containment shield shaping
BR112012017535A2 (pt) 2010-01-15 2019-09-24 Of Medicine And Dentistry Of New Jersey University uso de compostos de vanádio para cicatrização de osso
WO2013006798A1 (fr) * 2011-07-06 2013-01-10 University Of Medicine And Dentistry Of New Jersey Composés de vanadium en tant que compléments thérapeutiques pour une régénération et une réparation de cartilage
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
CA2820297C (fr) 2010-12-10 2019-06-25 University Of Medicine And Dentistry Of New Jersey Dispositifs implantables revetus de composites d'agent mimetique de l'insuline, et procedes associes
CN114177197A (zh) * 2011-03-07 2022-03-15 Cfm医药控股有限公司 用于维持哺乳动物体内血糖量正常的钒化合物的用途
PL231079B1 (pl) 2012-11-07 2019-01-31 Univ Jagiellonski Kompleksy wanadu z hydrazydohydrazonami, preparaty farmaceutyczne oraz zastosowanie kompleksów wanadu z hydrazydohydrazonami
NL2019605B1 (en) * 2017-09-22 2019-03-28 Cfm Pharma Holding B V Vanadyl and vanadate for use in reducing stress-induced metabolic derangement

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5448490A (en) * 1989-04-24 1990-11-16 Board Of Regents, The University Of Texas System Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue
US5565491A (en) 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
FR2729957B1 (fr) * 1995-01-31 1997-12-05 Maurel Sante Complexes organometalliques a base de sitosterols et d'acylglycerols et compositions pharmaceutiques et produits dietetiques en contenant.
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.

Also Published As

Publication number Publication date
NO20000446L (no) 2000-03-24
PT1001792E (pt) 2004-03-31
JP2001511454A (ja) 2001-08-14
CZ2000326A3 (cs) 2000-07-12
TR200000349T2 (tr) 2000-09-21
ES2207851T3 (es) 2004-06-01
AU8650598A (en) 1999-02-22
US20030211170A1 (en) 2003-11-13
AU738701B2 (en) 2001-09-27
ATE253373T1 (de) 2003-11-15
CZ299716B6 (cs) 2008-10-29
IL134259A (en) 2010-02-17
NL1006681C2 (nl) 1999-02-08
CA2298645C (fr) 2004-05-18
CA2298645A1 (fr) 1999-02-11
US6579540B1 (en) 2003-06-17
CN1270525A (zh) 2000-10-18
EA002574B1 (ru) 2002-06-27
WO1999006056A1 (fr) 1999-02-11
PL338415A1 (en) 2000-11-06
NO20000446D0 (no) 2000-01-28
IL134259A0 (en) 2001-04-30
EP1001792B1 (fr) 2003-11-05
NZ502613A (en) 2001-08-31
BR9811298A (pt) 2000-08-29
EP1001792A1 (fr) 2000-05-24
ID24870A (id) 2000-08-31
CN1104244C (zh) 2003-04-02
EA200000176A1 (ru) 2000-10-30
DE69819514T2 (de) 2004-09-23
DE69819514D1 (de) 2003-12-11

Similar Documents

Publication Publication Date Title
DK1001792T3 (da) Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
EE02971B1 (et) Droloksüfeeni või selle soolade kasutamine luuhaiguste vastase ravimi valmistamiseks
BR0109703A (pt) Derivados de piperazina
WO2003009838A1 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
SE9802208D0 (sv) Novel compounds
NO990833L (no) Farmas°ytiske forbindelser
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
ES2128043T3 (es) Uso de bis(amidinobencimidazoles) en la preparacion de un medicamento para inhibir la integrasa retroviral.
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
ATE289204T1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
DK0750616T3 (da) Syreadditionssalte af 2,3,4,5-tetrahydro-1H-3-benzazapinforbindelser
SE9802209D0 (sv) Novel compounds
CA2289017A1 (fr) Utilisation d'oxydes d'azote ou de promedicament a base de ces oxydes pour la prevention et le traitement therapeutique du cancer
PL339073A1 (en) Derivatives of benzoxazine and benzothiazine and their application in therapeutic agents
WO2001016096A3 (fr) Utilisation de bisulfonamides pour preparer des medicaments s'utilisant pour assurer la prophylaxie ou le traitement de l'hyperlipidemie
BR0115911A (pt) Uso de pirazolo[4,3-d]pirimidinas
ES2065855B1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
TR200201654T2 (tr) Benzamidin türevleri.
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
GR20010100390A (el) Χρηση του diclofenac h αποδεκτων αλατων αυτου για την αντιμετωπιση των εγκαυματων.
WO2001045717A3 (fr) COMPOSITION PHARMACEUTIQUE COMPRENANT UN COMPOSE DE VANADIUM PHYSIOLOGIQUEMENT ACCEPTABLE, UN SEL OU UN COMPLEXE DE CE COMPOSE ET AU MOINS UN CONSTITUANT CHOISI PARMI DES INHIBITEURS D'ECHANGEUR DE Na+/H+, DES INHIBITEURS DE CYCLO-OXYGENASE ET DES INHIBITEURS DE CASPASE